Relationship of soluble ST2 to pulmonary hypertension severity in patients undergoing cardiac resynchronization therapy
Open Access
- 1 December 2019
- journal article
- research article
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 11 (12) , 5362-5371
Abstract
Background: Pulmonary hypertension (PH) is an adverse prognostic marker in patients undergoing cardiac resynchronization therapy (CRT). We sought to determine the relation of biomarkers of fibrosis [soluble ST2 (sST2), galectin-3], wall stretch [amino terminal pro-brain natriuretic peptide (NT-proBNP)], and necrosis [high-sensitivity troponin-I (hsTnI)] to PH severity in CRT patients. Methods: Biomarkers and right ventricular systolic pressure (RVSP) were measured at CRT implant and 6-month later (n=111). PH was categorized into 3 groups based on RVSP: no (60 mmHg). Patients were categorized as progressors (worsened PH), persistent PH (no change) and regressors (improved PH). Endpoints were 6-month CRT response and 2-year major adverse cardiac event (MACE). Results: RVSP was associated with CRT nonresponse (P=0.02) and MACE (P=0.03). Severe PH patients had 5-fold increase risk for CRT nonresponse (OR 5.0, P=0.04) and MACE (HR 5.7, P=0.04) over non-PH patients. Progressors and persistent PH patients had >2-fold odds for CRT non-response (OR 2.8, P=0.45) and >11-fold increase in MACE compared to no PH patients or regressors (HR 11.6, P=0.02). Only NT-proBNP and sST2 were discernable between PH groups, with graded increase based on PH severity (both P≤0.02), and lower values in regressors versus non-regressors (both P≤0.01). Levels of sST2 decreased at 6 months in regressors (15 ng/mL, P=0.03) and increased slightly (3–8 ng/mL) in non-regressors, without difference for NT-proBNP (P=0.08). Conclusions: sST2 levels are related with PH severity in CRT patients. Serial sST2 changes after CRT implant suggests potential role to monitor PH after CRT.Keywords
This publication has 29 references indexed in Scilit:
- Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart FailureNew England Journal of Medicine, 2010
- Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients With Acute DyspneaCirculation: Heart Failure, 2009
- Usefulness of Pulmonary Artery Pressure by Echocardiography to Predict Outcome in Patients Receiving Cardiac Resynchronization Therapy Heart FailureThe American Journal of Cardiology, 2008
- Elevated Estimated Pulmonary Artery Systolic Pressure is Associated with an Adverse Clinical Outcome in Patients Receiving Cardiac Resynchronization TherapyPacing and Clinical Electrophysiology, 2007
- The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillatorEuropean Heart Journal, 2006
- Relation of Right Ventricular Peak Systolic Pressure to Major Adverse Events in Patients Undergoing Cardiac Resynchronization TherapyThe American Journal of Cardiology, 2006
- Left Ventricular Dyssynchrony Predicts Right Ventricular Remodeling After Cardiac Resynchronization TherapyJACC, 2005
- Improvement of apparently fixed pulmonary hypertension with cardiac resynchronization therapyThe Journal of Heart and Lung Transplantation, 2004
- Assessment of left ventricular ejection fraction and volumes by real-time, two-dimensional echocardiography. A comparison of cineangiographic and radionuclide techniques.Circulation, 1979
- Left ventricular volume from paired biplane two-dimensional echocardiography.Circulation, 1979